Frankfurt - Delayed Quote EUR

TME Pharma N.V. (0N6A.F)

0.2315 -0.0180 (-7.21%)
As of 11:20 AM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 0N6A.F

Recent News: 0N6A.F

View More
TME Pharma Publishes 2023 Financial Results and Provides Operating Update

TME Pharma Publishes 2023 Financial Results and Provides Operating Update
Business Wire 20 hours ago
TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer

TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
Business Wire 3 days ago

TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
Business Wire 23 days ago
TME Pharma Provides Results of First Exercise of Warrants Z

TME Pharma Provides Results of First Exercise of Warrants Z
Business Wire 29 days ago
TME Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for NOX-A12 Phase 2 Trial in Brain Cancer

TME Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for NOX-A12 Phase 2 Trial in Brain Cancer
Business Wire last month
TME Pharma Provides Results of Final Exercise of Warrants Y: Additional €854K Raised and Extension of Cash Runway From May Into July 2024

TME Pharma Provides Results of Final Exercise of Warrants Y: Additional €854K Raised and Extension of Cash Runway From May Into July 2024
Business Wire 2 months ago

TME Pharma Announces the End of the Convertible Debt Program With the Successful €1.48 Million Financing Intended for Buyback of All Outstanding Convertible Debt
Business Wire 2 months ago
TME Pharma Announces Final Median Overall Survival Data Reaching 19.9 Months for NOX-A12 Combination Regimen in GLORIA Brain Cancer Trial and Survival Rate 10-Fold Greater Than Standard of Care

TME Pharma Announces Final Median Overall Survival Data Reaching 19.9 Months for NOX-A12 Combination Regimen in GLORIA Brain Cancer Trial and Survival Rate 10-Fold Greater Than Standard of Care
Business Wire 2 months ago
TME Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities

TME Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities
Business Wire 2 months ago
TME Pharma Provides Update on Number of Outstanding Shares and Warrants Following First Warrant Y Exercise Period

TME Pharma Provides Update on Number of Outstanding Shares and Warrants Following First Warrant Y Exercise Period
Business Wire 3 months ago
TME Pharma Announces Successful Advice Meeting With US Food and Drug Administration on NOX-A12 Development in Brain Cancer

TME Pharma Announces Successful Advice Meeting With US Food and Drug Administration on NOX-A12 Development in Brain Cancer
Business Wire 3 months ago
TME Pharma Announces Further Improvement in Median Overall Survival at 19 Months Follow-up in GLORIA Brain Cancer Trial

TME Pharma Announces Further Improvement in Median Overall Survival at 19 Months Follow-up in GLORIA Brain Cancer Trial
Business Wire 4 months ago
View More

Related Tickers

ARGXb.XC
 
1AEA.MU argenx SE
346.00
-0.57%
 
0QW0.IL argenx SE
346.00
-0.36%
 
FTD.SG Financière de Tubize SA
92.40
-0.22%
 
0A3M.IL BioNTech SE
87.00
+0.58%
 
BTC.AX BTC Health Limited
0.0430
0.00%
 
PAB.AX Patrys Limited
0.0090
0.00%
 
PYC.AX PYC Therapeutics Limited
0.0920
-1.08%
 
ABNX.PA ABIONYX Pharma SA
1.0140
-0.39%
 
ZEALc.XC